A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs BIIB-092 (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Adverse reactions
  • Acronyms CN002-003
  • Sponsors Biogen; Bristol-Myers Squibb
  • Most Recent Events

    • 12 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 06 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 11 Sep 2015 Planned End Date changed from 1 May 2017 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top